New insights into the molecular pathogenesis of colorectal cancer

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 4, 2006, Pages 439-445

  Hung, Kenneth E ^a   Chung, Daniel C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CP 751871; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA GLYCOSYLASE MUTY; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ICG 001; INSM 18; IRINOTECAN; K RAS PROTEIN; LONAFARNIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PANITUMUMAB; PELITINIB; PERIFOSINE; PROTEIN MLH1; ROFECOXIB; SORAFENIB; SULINDAC; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER RESISTANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARDIOVASCULAR DISEASE; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CPG ISLAND; DNA METHYLATION; DNA REPAIR; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENOME IMPRINTING; HUMAN; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; NONHUMAN; PROMOTER REGION; REVIEW;

EID: 33847060569     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.10.005     Document Type: Review

References (50)

1. Jemal A., et al. Cancer statistics. CA Cancer J. Clin. 56 (2006) 106-130
2. O'Connell J.B., et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 96 (2004) 1420-1425
3. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
4. Jeter J.M., et al. Genetics of colorectal cancer. Oncology (Williston Park) 20 (2006) 269-276 discussion 285-266, 288-269
5. Al-Tassan N., et al. Inherited variants of MYH associated with somatic G:C → T:A mutations in colorectal tumors. Nat. Genet. 30 (2002) 227-232
6. Venesio T., et al. High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis. Gastroenterology 126 (2004) 1681-1685
7. Lipton L., et al. Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res. 63 (2003) 7595-7599
8. Sieber O.M., et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N. Engl. J. Med. 348 (2003) 791-799
9. Peterlongo P., et al. Increased frequency of disease-causing MYH mutations in colon cancer families. Carcinogenesis (2006) 10.1093/carcin/bgl1093 Epub ahead of print, June 14
10. Jenkins M.A., et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 312-314
11. Bjornsson H.T., et al. An integrated epigenetic and genetic approach to common human disease. Trends Genet. 20 (2004) 350-358
12. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
13. Toyota M., et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U S A 96 (1999) 8681-8686
14. Herman J.G., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U S A 95 (1998) 6870-6875
15. Shen L., et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst. 97 (2005) 1330-1338
16. Yamashita K., et al. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 4 (2003) 121-131
17. Weisenberger D.J., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38 (2006) 787-793
18. Jass J.R. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat. Clin. Pract. Oncol. 2 (2005) 398-405
19. Cunningham K.S., and Riddell R.H. Serrated mucosal lesions of the colorectum. Curr. Opin. Gastroenterol. 22 (2006) 48-53
20. Longacre T.A., and Fenoglio-Preiser C.M. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am. J. Surg. Pathol. 14 (1990) 524-537
21. Lazarus R., et al. The risk of metachronous neoplasia in patients with serrated adenoma. Am. J. Clin. Pathol. 123 (2005) 349-359
22. Sawyer E.J., et al. Molecular characteristics of serrated adenomas of the colorectum. Gut 51 (2002) 200-206
23. Yang S., et al. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am. J. Surg. Pathol. 28 (2004) 1452-1459
24. Konishi K., et al. Molecular differences between sporadic serrated and conventional colorectal adenomas. Clin. Cancer Res. 10 (2004) 3082-3090
25. Kambara T., et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53 (2004) 1137-1144
26. Kaneda A., and Feinberg A.P. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res. 65 (2005) 11236-11240
27. Rainier S., et al. Relaxation of imprinted genes in human cancer. Nature 362 (1993) 747-749
28. Cui H., et al. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 4 (1998) 1276-1280
29. Cui H., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299 (2003) 1753-1755
30. Woodson K., et al. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J. Natl. Cancer Inst. 96 (2004) 407-410
31. Sasaki J., et al. Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2. Int. J. Cancer 119 (2006) 80-83
32. Sakatani T., et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307 (2005) 1976-1978
33. Eguchi M., et al. ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med. Chem. 1 (2005) 467-472
34. Shiff S.J., and Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J. Exp. Med. 190 (1999) 445-450
35. Grosch S., et al. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736-747
36. Ciardiello F., and Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur. J. Cancer 39 (2003) 1348-1354
37. Cunningham D., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (2004) 337-345
38. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027
39. Hurwitz H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
40. Rychahou P.G., et al. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann. Surg. 243 (2006) 833-842
41. Crul M., et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 20 (2002) 2726-2735
42. Rowinsky E.K., et al. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J. Clin. Oncol. 17 (1999) 3631-3652
43. Emami K.H., et al. A small molecule inhibitor of {beta}-catenin/CREB-binding protein transcription. PNAS 101 (2004) 12682-12687
44. Arber N., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355 (2006) 885-895
45. Baron J.A., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) epub
46. Bertagnolli M.M., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355 (2006) 873-884
47. Gibson T.B., et al. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin. Colorectal. Cancer 6 (2006) 29-31
48. Erlichman C., et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 24 (2006) 2252-2260
49. Attard G., et al. Phase I trial involving the pharmacodynamic study of circulating tumor cells, of CP-751,871, a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel in patients with advanced cancer. J. Clin. Oncol. 24 18S (2006) 3023
50. Crul M., et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumors. Eur. J. Cancer 38 (2002) 1615-1621